.png)
TL;DRDDD (Defined Daily Dose) is the assumed average maintenance dose per day for a drug used for its main indication in adults, defined by the WHO Collaborating Centre for Drug Statistics Methodology. It is a measurement unit for drug utilisation, not a recommended or prescribed dose.
The DDD gives drug-consumption data a common denominator. Sales figures, prescription counts and package sizes are hard to compare across substances, strengths and countries. Expressing them in DDDs converts heterogeneous quantities into a single unit that reflects how much therapy a population actually consumed. The WHO Collaborating Centre in Oslo assigns one DDD per active substance, working with the WHO International Working Group on Drug Statistics Methodology, and publishes the values in the ATC/DDD Index that is updated annually.
A DDD is normally derived from the average adult dose recommended for the main indication reflected by the substance's ATC code. Where a standard body weight is needed, the calculation assumes a 70 kg adult. The recommended long-term maintenance dose is usually preferred over higher initial or loading doses, and doses for treatment take priority over doses for prevention unless prevention is the main indication.
No. The DDD is a technical unit for comparing consumption across drugs, populations and time. The WHO Collaborating Centre states plainly that the DDD does not necessarily reflect the recommended or prescribed daily dose, and that classification in the ATC/DDD system is not a recommendation for use. The dose an individual patient actually receives, the Prescribed Daily Dose (PDD), depends on age, weight, renal function, indication and disease severity, and can sit well above or below the DDD.
This distinction matters in practice. A DDD figure describes aggregate utilisation, not clinical intent. Using it to justify a dose at the point of care, or reading a single DDD value as "the correct dose", misreads the metric. For a substance whose real-world dosing has drifted from the WHO value, DDD-based consumption will systematically over- or under-state the number of treated patients, which is a known limitation of the method.
The ATC (Anatomical Therapeutic Chemical) classification and the DDD are two halves of one methodology, maintained together by the same WHO Collaborating Centre. The ATC system sorts active substances into a five-level hierarchy, with the 5th level identifying the individual chemical substance. A DDD is assigned at that substance level: only one DDD is set per ATC code and route of administration, for example a separate value for the oral and the parenteral form.
Because every substance carries both an ATC code and a DDD, utilisation can be aggregated at any ATC level and expressed in standardised indicators. The most common is DDD per 1000 inhabitants per day, which estimates the share of a population on a given drug or drug class on an average day. Ten DDD per 1000 inhabitants per day, for instance, corresponds to roughly one percent of the population receiving that therapy daily over the year analysed. For inpatient care, DDD per 100 bed-days is the analogous indicator.
| Attribute | DDD (Defined Daily Dose) | PDD (Prescribed Daily Dose) |
|---|---|---|
| Purpose | Measurement unit for drug utilisation statistics | Actual daily dose prescribed to patients |
| Set by | WHO Collaborating Centre, Oslo | Prescriber, per patient |
| Assigned at | ATC 5th level (substance) plus route | Individual prescription |
| Reference weight | 70 kg adult where needed | Real patient |
| Is it a dosing recommendation? | No | Reflects clinical intent |
In Germany the DDD is the standard denominator for measuring drug use. It underlies the analyses in the annual Arzneiverordnungs-Report and is used in health-services research to track prescribing trends, benchmark antibiotic consumption and support pricing and economic comparisons between substances. Because the WHO deliberately keeps ATC codes and DDDs stable over time, long-run trend analysis across years and countries stays methodologically consistent.
Reading DDD-based statistics correctly means anchoring them to the underlying substance and route. This is where a consolidated substance view helps: to interpret a consumption figure you need the ATC code, the route, the strengths on the market and the products behind them.
pharmazie.com does not replace the WHO Collaborating Centre as the source of DDD values, the ATC/DDD Index remains the authoritative reference. What the platform adds is the surrounding data needed to apply a DDD to real products: the ATC code per product and the substance dossier (Wirkstoffdossier) that consolidates a single active ingredient across the German market, including its ATC assignment, strengths, dosage forms and the individual products carrying it. That substance-level context lets a market-access or research team map a utilisation figure back to the ATC 5th level and the products behind it in one search.
One honest limitation: pharmazie.com is a reference and consolidation layer for ATC and substance data, not a source of official DDD values, and it does not compute national DDD-per-1000 utilisation statistics for you. The current DDD for a substance should always be taken from the WHO ATC/DDD Index, and the utilisation calculation itself sits with the analyst or the health-services data source.
